Search research articles
Contact Us
Filters
Showing results (251-260 of 263) with videos related to
Page
of 27
Sort By:
Life Sciences
|
June 4, 2021
Effects of three types of bariatric interventions on myocardial infarct size and vascular function in rats with type 2 diabetes mellitus
Oleg V Kornyushin, Dmitry L Sonin, Alexander S Polozov, et al.
Tsitologiia
|
September 7, 2018
ITLN1, PPARg AND TNFa GENE EXPRESSION IN VISCERAL ADIPOSE TISSUE
T S Usenko, V V Miroshnikova, E A Bazhenova, et al.
Journal of Crohn'S & Colitis
|
February 4, 2023
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions
Mathieu Uzzan, Yoram Bouhnik, Maria Abreu, et al.
Implementation Science : IS
|
September 11, 2019
Correction to: A repeated cross-sectional study of clinicians' use of psychotherapy techniques during 5 years of a system-wide effort to implement evidence-based practices in Philadelphia
Rinad S Beidas, Nathaniel J Williams, Emily M Becker-Haimes, et al.
Implementation Science : IS
|
June 23, 2019
A repeated cross-sectional study of clinicians' use of psychotherapy techniques during 5 years of a system-wide effort to implement evidence-based practices in Philadelphia
Rinad S Beidas, Nathaniel J Williams, Emily M Becker-Haimes, et al.
Plos One
|
February 25, 2026
Protocol for testing global neuronal workspace and integrated information theories of consciousness in non-human primates and mice
Matilda Gibbons, Ethan G McBride, Raghuram Holenarasipura Venkatasubbaiah, et al.
Lancet (London, England)
|
November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
The New England Journal of Medicine
|
July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
Laurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
JAMA
|
July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Lancet (London, England)
|
June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Marc Ferrante, Remo Panaccione, Filip Baert, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 263) with videos related to
Sort By:
Page
of 27
Life Sciences
|
June 4, 2021
Effects of three types of bariatric interventions on myocardial infarct size and vascular function in rats with type 2 diabetes mellitus
Oleg V Kornyushin, Dmitry L Sonin, Alexander S Polozov, et al.
Tsitologiia
|
September 7, 2018
ITLN1, PPARg AND TNFa GENE EXPRESSION IN VISCERAL ADIPOSE TISSUE
T S Usenko, V V Miroshnikova, E A Bazhenova, et al.
Journal of Crohn'S & Colitis
|
February 4, 2023
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions
Mathieu Uzzan, Yoram Bouhnik, Maria Abreu, et al.
Implementation Science : IS
|
September 11, 2019
Correction to: A repeated cross-sectional study of clinicians' use of psychotherapy techniques during 5 years of a system-wide effort to implement evidence-based practices in Philadelphia
Rinad S Beidas, Nathaniel J Williams, Emily M Becker-Haimes, et al.
Implementation Science : IS
|
June 23, 2019
A repeated cross-sectional study of clinicians' use of psychotherapy techniques during 5 years of a system-wide effort to implement evidence-based practices in Philadelphia
Rinad S Beidas, Nathaniel J Williams, Emily M Becker-Haimes, et al.
Plos One
|
February 25, 2026
Protocol for testing global neuronal workspace and integrated information theories of consciousness in non-human primates and mice
Matilda Gibbons, Ethan G McBride, Raghuram Holenarasipura Venkatasubbaiah, et al.
Lancet (London, England)
|
November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
The New England Journal of Medicine
|
July 17, 2024
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
Laurent Peyrin-Biroulet, J Casey Chapman, Jean-Frederic Colombel, et al.
JAMA
|
July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
Edouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Lancet (London, England)
|
June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Marc Ferrante, Remo Panaccione, Filip Baert, et al.
Page
of 27